CIRIUM
11.3.2021 07:27:13 CET | Business Wire | Press release
Cirium , the aviation analytics company, which is part of RELX, today announces the acquisition of Migacore , a travel technology start-up that has demonstrated how applying advanced machine learning (ML) techniques to online data sources can help airlines stay ahead of changes in passenger demand.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210310006079/en/
Migacore has worked with some of the world’s most advanced carriers, such as Lufthansa and Singapore Airlines, to translate data from online news, search, social media, events and exhibitions, into signals that can help predict real-world travel demand.
After a series of successful airline trials, the Migacore team and technology are joining Cirium, which will help to scale the capabilities. The Migacore team will not only gain access to Cirium’s data and resources, but also to the group’s commercial reach across global aviation.
Airline demand models have traditionally been built around comparing current booking activity against historic trends, with the ticket offers raised or lowered to ensure that a flight is filled at optimum fare levels. The search was already on to improve on this but has been accelerated by the unprecedented collapse of flying during the pandemic.
“The airline industry has been experimenting with new sources of demand data for some time, but the pandemic has now made this an absolute necessity. Past booking patterns today give virtually no guide to current demand,” said Kevin O’Toole, chief strategy officer at Cirium.
“Migacore is not alone in looking for new demand signals, but it really stands out. Their airline partners were clearly impressed with how the team had taken time to understand and integrate with the highly automated workflow around Revenue Management. And we were impressed too,” said O’Toole.
“Integrating our forecasting capabilities into the Cirium portfolio will bring forward the new model that the market has needed for some time, allowing airlines to better forecast the intent to travel. Ultimately that means better matching between market demand and the airline offer, which should be good for travelers and carriers alike,” said Abheer Kolhatkar, chief executive officer and co-founder at Migacore.
The plan is to scale the existing service under the Cirium brand and to make similar forecasting available to clients across air travel and into aerospace, aircraft finance and beyond.
For further information please visit www.cirium.com and follow Cirium updates via LinkedIn and Twitter .
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.
About RELX
RELX is a global provider of information-based analytics and decision tools for professional and business customers. The Group serves customers in more than 180 countries and has offices in about 40 countries. It employs over 33,000 people, of whom almost half are in North America. The shares of RELX PLC, the parent company, are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX. The market capitalisation is approximately £33.3bn, €39bn, $46.5bn.
About Migacore
Migacore is a tech start-up founded and built by machine learning experts, focusing on bringing predictive demand forecasting for airlines. Migacore was one of the first start-ups to join IAG’s Hangar 51 program, is an alumni of Accelerate@IATA — a program led by IATA and Silicon Valley’s platform Plug and Play—and was one of the first start-ups to graduate from Singapore Airline’s KrisLab scheme. Migacore’s innovation has been featured heavily at key industry events including ATPCO’s Elevate events 2019 and 2018 , Applied Machine Learning Days (AMLD) 2020 , Entrepreneur First 2017 and NDR – The Artificial Intelligence Conference 2018 , and was named as Plug and Play’s 11 start-ups to watch for 2020 .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310006079/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
